The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa.
Tembeka SinekeDenise EvansKathryn SchnippelHeleen van AswegenRebecca BerhanuNozipho MusakwaElisabet LönnmarkLawrence LongSydney RosenPublished in: Health and quality of life outcomes (2019)
Results show that DR-TB had a substantial impact on patients' quality of life, but that AEs during the early months on treatment may be responsible for reducing HRQoL even further. Our findings highlight the negative effects of injectable agents on HRQoL. Patients require an integrative patient-centered approach to deal with DR-TB and HIV and the potential overlapping toxicities which may be worsened by concurrent treatment.
Keyphrases
- drug resistant
- south africa
- end stage renal disease
- ejection fraction
- newly diagnosed
- mycobacterium tuberculosis
- hiv positive
- chronic kidney disease
- multidrug resistant
- prognostic factors
- peritoneal dialysis
- emergency department
- squamous cell carcinoma
- human immunodeficiency virus
- hiv infected
- antiretroviral therapy
- radiation therapy
- men who have sex with men
- cystic fibrosis
- pulmonary tuberculosis
- replacement therapy
- hyaluronic acid
- editorial comment
- electronic health record